Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Prostatic Neoplasms 1Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer 1Ovarian Neoplasms 1Melanoma 1Locally Advanced Colorectal Cancer 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

apatinib 2Hyperthermic Intraperitoneal Chemotherapy 2Gastrectomy 2trastuzumab deruxtecan 1taxane 1sintilimab 1pembrolizumab 1durvalumab 1disitamab vedotin 1cabozantinib 1Taxes 1Tadalafil 1SHR-1701 1S 1 (combination) 1Platinum 1Paclitaxel 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Indocyanine Green 1Immunotherapy, Adoptive 1Cytoreduction Surgical Procedures 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric Adenocarcinoma × SHR-1701 × 1 year × Clear all
NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡